- Open
- 118.60
- High
- 123.40
- Low
- 118.00
- Close
- 123.40
- Change
- +3.80 (3.18%)
- Volume
- 518,152
| 30 Oct 2026 | 17:40:23 | Holding(s) in Company |
| 30 Oct 2026 | 07:00:05 | PureTech Health Wins 2026 Prix Galien USA Award |
| 29 Oct 2026 | 11:00:00 | PRTC's Celea Appoints Paul Audhya, MD, MBA, as CMO |
| 26 Oct 2026 | 07:00:10 | PRTC's Gallop Presents Ph1b LYT-200 Data at ESMO |
| 21 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 29 Apr 2026 | Annual Report and Accounts 2025 | |
| 19 May 2025 | Annual Report and Accounts (to 2024-12-31) |
PureTech Health PLC is a biotherapeutics company that focuses on the clinical development of therapies for severe diseases, including immunological, fibrotic, and inflammatory conditions. The company operates a hub-and-spoke model, advancing programs through Founded Entities, which are companies it has established to develop specific therapeutic candidates. PureTech generates revenue through equity interests and potential milestone payments from these entities, while also attracting external capital to support its initiatives. It operates primarily in the biotechnology sector, with a presence in Boston and the UK.
| 30 Oct 2026 | 17:40:23 | Holding(s) in Company |
| 30 Oct 2026 | 07:00:05 | PureTech Health Wins 2026 Prix Galien USA Award |
| 29 Oct 2026 | 11:00:00 | PRTC's Celea Appoints Paul Audhya, MD, MBA, as CMO |
| 26 Oct 2026 | 07:00:10 | PRTC's Gallop Presents Ph1b LYT-200 Data at ESMO |
| 21 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 29 Apr 2026 | Annual Report and Accounts 2025 | |
| 19 May 2025 | Annual Report and Accounts (to 2024-12-31) |
PureTech Health PLC is a biotherapeutics company that focuses on the clinical development of therapies for severe diseases, including immunological, fibrotic, and inflammatory conditions. The company operates a hub-and-spoke model, advancing programs through Founded Entities, which are companies it has established to develop specific therapeutic candidates. PureTech generates revenue through equity interests and potential milestone payments from these entities, while also attracting external capital to support its initiatives. It operates primarily in the biotechnology sector, with a presence in Boston and the UK.
| 19 Oct 2026 | 07:00:08 | PRTC's Gallop to Present Ph1b LYT-200 Data at ESMO |
| 19 Oct 2026 | 07:00:08 | PRTC's Gallop to Present Ph1b LYT-200 Data at ESMO |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £363m | -0.5% | |
PRTCPuretech Health PLC | £303m | -0.1% |
| £104m | -0.1% | |
| £16m | -0.1% | |
| £11m | -0.1% | |
| £10m | -0.0% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £363m | -0.5% | |
PRTCPuretech Health PLC | £303m | -0.1% |
| £104m | -0.1% | |
| £16m | -0.1% | |
| £11m | -0.1% | |
| £10m | -0.0% |
